Skip to main content

Table 1 Characteristics of the participants at baseline and 1st post-trial visit

From: Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

CharacteristicsBaselineP1st post-trial visitP
Fenofibrate (n = 484)Placebo (n = 456)Fenofibrate (n = 395)Placebo (n = 370)
Age61.4 ± 6.262.2 ± 6.70.0467.2 ± 6.367.6 ± 6.60.32
Sex0.96  0.59
 Male388 (80.2%)364 (79.8%) 319 (80.8%)292 (78.9%) 
 Female96 (19.8%)92 (20.2%) 76 (19.2%)78 (21.1%) 
Years of diabetes9.2 ± 6.69. 6 ± 6.60.3714.6 ± 6.515.2 ± 6.60.22
Ethnicity0.17  0.51
 White365 (75.4%)362 (79.4%) 305 (77.2%)294 (79.5%) 
 Non-White119 (24.6%)94 (20.6%) 90 (22. 8%)76 (20.5%) 
CVD history0.93  0.98
 Yes195 (40.3%)186 (40.8%) 153 (38.7%)142 (38.4%) 
 No289 (59.7%)270 (59.2%) 242 (61.3%)228 (61.6%) 
BG trial assignment0.36  0.36
 Intensive group251 (51.8%)222 (48.7%) 203 (51.4%)177 (47.8%) 
 Standard group233 (48.2%)234 (51.3%) 192 (48.6%)193 (52.2%) 
HbA1c (%)8.4 ± 1.18.4 ± 1.00.947.9 ± 1.97.6 ± 1.30.07
SBP (mm Hg)134.1 ± 17.6133.9 ± 18.60.87131.0 ± 17.1131.8 ± 17.30.66
CHOL (mg/dl)187.0 ± 38.5189.0 ± 42.10.45154.6 ± 42.5152.8 ± 32.80.64
TG (mg/dl)327.2 ± 125.3325.0 ± 154.20.81216.6 ± 124.1222.7 ± 115.20.61
VLDL-C (mg/dl)61.2 ± 18.661.2 ± 25.40.9741.4 ± 20.842.63 ± 20.10.55
LDL-C (mg/dl)96.3 ± 32.098.4 ± 32.90.3479.2 ± 32.776.6 ± 26.10.38
HDL-C (mg/dl)29.5 ± 3.829.5 ± 3.70.7633.9 ± 7.333.6 ± 7.20.60
  1. Plus–minus values are mean ± SD
  2. HbA1c glycated hemoglobin A1c, SBP systolic blood pressure, CHOL total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very low-density lipoprotein cholesterol